Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. NPJ Precis Oncol 2022 Nov 23;6(1):86
Date
11/24/2022Pubmed ID
36418474Pubmed Central ID
PMC9684405DOI
10.1038/s41698-022-00329-wScopus ID
2-s2.0-85142447563 (requires institutional sign-in at Scopus site) 18 CitationsAbstract
The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.
